Currently, the CLDN18.2 monoclonal antibody IMAB362 has received FDA approval for application as a first‐line therapy in patients diagnosed with locally advanced unresectable or metastatic HER2‐negative GC/GEJ who exhibit CLDN18.2 positivity.[21] Moreover, Zhu and co‐workers reported the CLDN18.2‐targeted nuclear imaging,[25] indicating the feasibility of utilizing CLDN18.2 for GC diagnosis. The gene discussed is ERBB2; the disease is gastric cancer.